Background/Aims: In the absence of effective treatments for dementia, major efforts are being directed towards identifying the risk factors of the prodromal phase of the disease. We report the incidence rates of mild cognitive impairment (MCI) in a Spanish population sample and assess the effect of depression at baseline on incident MCI (or MCI subtypes) at a 3-year follow-up. Methods: A total of 1,642 participants (age ≥50 years) were examined as part of a Spanish nationally representative longitudinal study. MCI was defined as the presence of cognitive concerns, objective evidence of impairment in one or more cognitive domains, preservation of independence in functional abilities, and no dementia. Depression was assessed through an adaptation of the Composite International Diagnostic Interview (CIDI 3.0). Binary and multinomial logistic regression analyses were carried out to assess the associations. Results: The overall MCI incidence rate was 33.19 (95% CI = 26.02, 43.04) per 1,000 person-years. Depression at baseline predicted the onset of MCI at follow-up after controlling for sociodemographics, cognitive functioning, and other physical health conditions (OR = 2.79; 95% CI = 1.70, 4.59). The effect of baseline depression on incident MCI subtypes was as follows: amnestic MCI, OR = 3.81 (95% CI = 1.96, 7.43); nonamnestic MCI, OR = 2.03 (95% CI = 0.98, 4.21). Conclusion: Depression significantly increases the risk for MCI. Targeting depression among those at risk for dementia may help delay or even prevent the onset of dementia.

Keywords:
Mild cognitive impairment, Depression, Risk factor, Incidence, Population-based study
1.
Alzheimer's Disease International: World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International (ADI), London.
2.
Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al: Mild cognitive impairment. Arch Neurol 2009;66:1447-1455.
3.
Brodaty H, Heffernan M, Kochan N, Draper B, Trollor JN, Reppermund S, et al: Mild cognitive impairment in a community sample: the Sydney Memory and Ageing Study. Alzheimers Dement 2013;9:310-317.
4.
Di Carlo A, Lamassa M, Baldereschi M, Inzitari M, Scafato E, Farchi G, et al: CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007;68:1909-1916.
5.
Cooper C, Sommerlad A, Lyketsos CG, Livingston G: Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry 2015;172:323-334.
6.
Apostolova LG, Cummings L: Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 2008;25:115-126.
7.
Byers AL, Yaffe K: Depression and risk of developing dementia. Nat Rev Neurol 2011;7:323-331.
8.
Xu W, Tan LL, Wang H-F, Jiang T, Tan M-S, Tan LL, et al: Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2015;86:1299-1306.
9.
Barnes DE, Yaffe K: The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011;10:819-828.
10.
Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al: Depression, apolipoprotein E genotype, and the Incidence of mild cognitive impairment. Arch Neurol 2006;63:435-440.
11.
Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K: Depressive symptoms, vascular disease, and mild cognitive impairment. Arch Gen Psychiatry 2006;63:273-280.
12.
Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, et al: Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013;70:374-382.
13.
Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW, et al: Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 2013;81:2032-2038.
14.
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Inter Med 2004;256:183-194.
15.
Dlugaj M, Weimar C, Wege N, Verde PE, Gerwig M, Dragano N, et al: Prevalence of mild cognitive impairment and its subtypes in the Heinz Nixdorf Recall study cohort. Dement Geriatr Cogn Disord 2010;30:362-373.
16.
Edwards ER, Spira AP, Barnes DE, Yaffe K: Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia. Int J Geriatr Psychiatry 2009;24:716-722.
17.
Rozzini L, Vicini Chilovi B, Conti M, Delrio I, Borroni B, Trabucchi M, et al: Neuropsychiatric symptoms in amnestic and nonamnestic mild cognitive impairment. Dement Geriatr Cogn Disord 2007;25:32-36.
18.
Shahnawaz Z, Reppermund S, Brodaty H, Crawford JD, Draper B, Trollor JN, et al: Prevalence and characteristics of depression in mild cognitive impairment: the Sydney Memory and Ageing Study. Acta Psychiatr Scand 2013;127:394-402.
19.
Garin N, Olaya B, Moneta MV, Miret M, Lobo A, Ayuso-mateos JL, et al: impact of multimorbidity on disability and quality of life in the Spanish older population. PLoS One 2014;9:e111498.
20.
Lobo A, Ezquerra J: “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1979;3:289-202.
21.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B: Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-858.
22.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
23.
Lara E, Koyanagi A, Olaya B, Lobo A, Miret M, Tyrovolas S, et al: Mild cognitive impairment in a Spanish representative sample: prevalence and associated factors. Int J Geriatr Psychiatry 2016;31:858-867.
24.
Morris J, Heyman A, Mohs R: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
25.
The Psychological Corporation: The WAIS III-WMS III Updated Technical Manual. San Antonio, The Psychological Corporation, 2002.
26.
Katz S, Ford A, Moskowitz R, Jackson B, Jaffe M: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
27.
Dlugaj M, Winkler A, Dragano N, Moebus S, Jöckel K-H, Erbel R, et al: Depression and mild cognitive impairment in the general population: results of the Heinz Nixdorf Recall Study. J Alzheimers Dis 2014;45:53-68.
28.
Haro JM, Arbabzadeh-Bouchez S, Brugha TS, De Girolamo G, Guyer ME, Jin R, et al: Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res 2006;15:167-180.
29.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC, 1994.
30.
Cabello M, Caballero FF, Chatterji S, Cieza A, Ayuso-Mateos JL: Risk factors for incidence and persistence of disability in chronic major depression and alcohol use disorders: longitudinal analyses of a population-based study. Health Qual Life Outcomes 2014;12:186.
31.
Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H: Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 2015;11:718-726.
32.
Cations M, Withall A, Low LF, Draper B: What is the role of modifiable environmental and lifestyle risk factors in young onset dementia? Eur J Epidemiol 2016;31:107-124.
33.
Cooper C, Sommerlad A, Lyketsos CG, Livingston G: Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry 2015;172:323-334.
34.
Bull FC, Maslin TS, Armstrong T: Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health 2009;6:790-804.
35.
World Health Organization: Global Physical Activity Questionnaire (GPAQ): Analysis Guide. Geneva, WHO, 2012. http://www.who.int/chp/steps/GPAQInstrumentandAnalysisGuidev2.pdf.
36.
World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation, 2000.
37.
World Health Organization: Global status report on alcohol and health. 2014. http://www.who.int/substance_abuse/publications/global_alcohol_report/en/.
38.
World Health Organization: A global brief for hypertension. 2013. http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf.
39.
Cohen J: Statistical power analysis for the behavioral sciences. New York, Academic Press, 1988.
40.
Luck T, Riedel-Heller, SG, Luppa M, Wiese B, Wollny A, Wagner M, et al: Risk factors for incident mild cognitive impairment - results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand 2010;121:260-272.
41.
Peduzzi P, Concato J, Holford T, Feinstein A: A simulation study of the number of events per variable per logistic regression analyses. J Clin Epidemiol 1996;49:1373-1379.
42.
Luck T, Luppa M, Briel S, Riedel-Heller SG: Incidence of mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 2010;29:164-175.
43.
Manly JJ, Tang M, Schupf N, Stern Y, Vonsattel J-PG, Mayeux R: Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008;63:494-506.
44.
Ravaglia G, Forti P, Lucicesare A, Rietti E, Pisacane N, Mariani E, et al: Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort. Am J Geriatr Psychiatry 2008;16:834-843.
45.
Ward A, Arrighi HM, Michels S, Cedarbaum JM: Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement 2012;8:14-21.
46.
Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC: Mild cognitive impairment : prevalence and incidence according to different diagnostic criteria: results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry 2003;182:449-454.
47.
Lopez OL, Becker JT, Chang YF, Sweet RA, DeKosky ST, Gach MH, et al: Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012;79:1599-1606.
48.
Tervo S, Kivipelto M, Hänninen T, Vanhanen M, Hallikainen M, Mannermaa A, et al: Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004;17:196-203.
49.
Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J, et al: Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord 2012;26:335-343.
50.
Ganguli M, Snitz B, Saxton J, Chang C-CH, Lee C-W, Vander Bilt J, et al: Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011;68:761-767.
51.
Loewenstein DA, Acevedo A, Small BJ, Agron J, Crocco E, Duara R: Stability of different subtypes of mild cognitive impairment among the elderly over a 2- to 3-year follow-up period. Dement Geriatr Cogn Disord 2009;27:418-423.
52.
Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A: Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. J Alzheimers Dis 2012;31:265-275.
53.
Artero S, Ancelin M-L, Portet F, Dupuy A, Berr C, Dartigues J-F, et al: Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry 2008;79:979-984.
54.
Dean K, Oulhaj A, Zamboni G, DeJager CA, Wilcock GK: Role of depression in predicting time to conversion to mild cognitive impairment. Am J Geriatr Psychiatry 2014;22:727-734.
55.
Caracciolo B, Bäckman L, Monastero R, Winblad B, Fratiglioni L: The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry 2011;82:788-793.
56.
Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, et al: Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry 2014;171:572-581.
57.
Goveas JS, Espeland MA, Woods NF, Wassertheil-Smoller S, Kotchen JM: Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 2011;59:57-66.
58.
Kida J, Nemoto K, Ikejima C, Bun S, Kakuma T, Mizukami K, et al: Impact of depressive symptoms on conversion from mild cognitive impairment subtypes to Alzheimer's disease: a community-based longitudinal study. J Alzheimers Dis 2016;51:405-415.
59.
López OL, Jagust WJ, Dulberg C, Becker JT, DeKosky S, Fitzpatrick A, et al: Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 2003;60:1394-1399.
60.
Dotson VM, Beydoun MA, Zonderman AB: Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010;75:27-34.
61.
Luck T, Luppa M, Briel S, Matschinger H, König HH, Bleich S, et al: Mild cognitive impairment: incidence and risk factors: results of the Leipzig Longitudinal Study of the Aged. J Am Geriatr Soc 2010;58:1903-1910.
62.
Panza F, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ, et al: Depressive symptoms, vascular risk factors and mild cognitive impairment: the Italian Longitudinal Study on Aging. Dement Geriatr Cogn Disord 2008;25:336-346.
63.
Cherbuin N, Rajeev R-M, Kumar R, Jacomb K, Easteal S, Christensen H, et al: Risk Factors of transition from normal cognition to mild cognitive disorder: the PATH through Life Study. Dement Geriatr Cogn Disord 2009;28:47-55.
64.
Bennett S, Thomas AJ: Depression and dementia: cause, consequence or coincidence? Maturitas 2014;79:184-190.
65.
Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF, et al: Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 2008;10:345-357.
66.
Hermida AP, McDonald WM, Steenland K, Levey A: The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link? Expert Rev Neurother 2012;12:1339-1350.
67.
Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, et al: Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161-167.
68.
Alexopoulos GS: Vascular disease, depression, and dementia. J Am Geriatr Soc 2003;51:1178-1180.
69.
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF: Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013;202:329-335.
70.
Mirza SS, De Bruijn RFAG, Direk N, Hofman A, Koudstaal PJ, et al: Depressive symptoms predict incident dementia during short- but not long-term follow-up period. Alzheimers Dement 2014;10:S323-S329.
71.
Ganguli M: Depression, cognitive impairment and dementia: why should clinicians care about the web of causation. Indian J Psychiatry 2009;51:S29-S34.
72.
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al: Cumulative use of strong anticholinergic medications and incident dementia. JAMA Intern Med 2015;175:401-407.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.